Apolipoprotein E3-Leiden (APOE* 3-Leiden) transgenic mice have been studied to identify factors modulating chy lomicron and VLDL remnant lipoprotein metabolism. Transient elevated levels of VLDL/LDL-sized lipoproteins occurred in these mice with maximal levels during the pe riod of rapid growth (optimum at 45 d of age). After about 100 d of age, serum cholesterol and triglyceride levels stabi lized to slightly elevated levels as compared to control mice. The expression of the APOE*3-Leiden transgene was not age-dependent. In young mice the in vivo hepatic produc tion of VLDL-triglycerides was 50% increased as compared to older mice. This is sustained by in vivo VLDL-apo B turnover studies showing increased (75%) VLDL-apo B se cretion rates in young mice, whereas the VLDL-apo B clear ance rate appeared not to be age dependent.
Introduction
In Western society people spend most of their life span under nonfasting conditions, As a result, there is a continuous release into the circulation of newly synthesized intestinal and hepatic lipoproteins, i.e., chylomicrons and VLDL lipoproteins. Nor mally, the remnants of these lipoproteins are rapidly removed from the circulation via receptor-mediated uptake in the liver. Apo E is a structural component of these remnant lipoproteins and serves as a ligand in the receptor mediated uptake by the liver (1, 2) . In patients suffering from familial dysbetalipopro teinemia (FD),1 a defective apo E leads to impaired hepatic uptake of remnant lipoproteins (1) . The consequent accumula tion of these lipoproteins leads to a predisposition of these pa tients to coronary and/or peripheral atherosclerosis (1, 3) .
Several in vivo and in vitro studies have demonstrated the unequivocal role of apo E in remnant lipoprotein metabolism (4, 5) . However, in homozygous carriers of the mutant APOE*2(Argl58-»Cys) allele, the presence of binding defec tive apo E2 does not explicitly result in the accumulation of remnant lipoproteins. Obviously, other environmental or ge netic factors interfere with remnant metabolism (1) .
In humans, heterozygosity for the rare mutant APOE* 3-Leiden allele is also associated with an accumulation of rem nant lipoproteins due to an impaired remnant clearance, de spite the presence of normal apo E (6) . Thus, in carriers of the apo E3-Leiden mutation, FD is inherited in a dominant fash ion although also in this case, additional environmental and genetic factors do modulate the severity of the disease.
Because of heterogeneity in environmental and genetic background, these additional factors can hardly be studied in humans. Therefore, to elucidate subtle factors that may modu late the metabolism of remnant lipoproteins, a suitable experi mental animal model is required. Experimental animals, like inbred mice and rats, efficiently remove remnant lipoproteins, even under severe dietary stress conditions (7) and are thus less suitable for these studies. Recently, we reported that transgenic mice expressing the human APOE*3-Leiden muta tion also demonstrate a hyperlipidemic phenotype (8). Fur thermore, in these mice, severe hyperlipidemia was observed after feeding high fat/cholesterol-containing diets which posi tively correlated with the level of expression of the transgene 1. Abbreviations used in this paper: FCR, fractional catabolic rate; FD, familial dysbetalipoproteinemia; HFC, high fat/cholesterol; SR, secretion rate. (9) . In addition, on high fat/cholesterol-containing diets the high expressing lines developed atherosclerotic lesions of which the severity was positively correlated with serum levels of cholesterol-rich remnant lipoproteins. Thus, also in these transgenic mice apo E3-Leiden behaves like a dominant trait in the accumulation of remnant lipoproteins.
We reasoned that APOE*3-Leiden mice display a defect in plasma clearance of remnant lipoproteins which allows us to study the effect of more subtle factors involved in remnant me tabolism under highly standardized conditions. The present study shows that in APOE*3-Leiden transgenic mice the plasma level of VLDL remnants is strongly influenced by age and gender related factors. Age appeared to affect the hepatic VLDL production rate, whereas gender modulates both the VLDL production and clearance rate.
Methods
Animals. Transgenic mice of line No. 2, heterozygous for the expres sion of the human APO E*3-Leiden and human APOC1 gene, were used (8). Transgenic and nontransgenic littermates were obtained by breeding with C57BL/6J mice (The Broekman Institute bv, Someren, The Netherlands). Mice of the F5 and F6 generation were included in the trials. Transgenic mice were identified by sandwich ELISA for the presence of human apo E in the serum (for method see below). Immediately after weaning (at age 25 d) mice were equally divided into two groups, consisting of female and male transgenic or nontransgenic mice. One group of mice was fed a regular mouse diet (SRM-A; Hope Farms, Woerden, The Netherlands), and the other group of mice was fed a semisynthetic high fat/cholesterol (HFC) diet. This HFC diet is a basic semisynthetic diet, which was composed essentially according to Nishina et al, (7) , supplemented with cocoa butter (15%, by wt) and cholesterol (0.25%, by wt) and was pur chased from Hope Farms. Mice were housed under standard condi tions in conventional cages and given free access to food and water. None of the transgenic or nontransgenic mice were lost during the study.
Lipid and lipoprotein analysis. After a 12-h fasting period, mice were weighed and ^ 50 jxl of blood was obtained from each individ ual mouse through tail bleeding. Blood samples were taken at differ ent time points as indicated in the figures for both diets. Total serum cholesterol and triglyceride levels (without measuring free glycerol) were measured enzymatically using commercially available kits (No. 236691; Boehringer Mannheim, Mannheim, Germany and No. 337-B; Sigma Chemical Co., St. Louis, MO).
For size fractionation of lipoproteins, some 200 fxl of pooled se rum (from at least 12 mice), was injected onto a 25 ml Superose 6B column (Pharmacia Fine Chemicals, Uppsala, Sweden) connected to an HPLC pump system and eluted at a constant flow rate of 0,5 ml/ min with PBS, pH 7.4. The effluent was collected in 0.5-ml fractions. Cholesterol and triglyceride concentrations in lipoprotein fractions were measured enzymatically, using kits No. 236691 and 701904 (Boehringer Mannheim), respectively.
Human A p o E3-Leiden protein measurements. Human apo E con centrations were measured by sandwich ELISA. Affinity purified polyclonal goat anti-human apo E antibodies were used for coating. Affinity purified polyclonal rabbit anti-hum an apo E antibodies were used as second antibodies. Thereafter, the plates were incubated with swine anti-rabbit IgG antibodies conjugated to horseradish peroxi dase. Finally, horseradish peroxidase detection was performed using horseradish peroxidase substrate tetramethylbenzidine. Pooled plasma from healthy human subjects with known apo E level, was used as a standard.
Human apo E and mouse Ldlr m R N A measurements in the liver. Total RNA was isolated from liver using the R N A Z O L procedure (Cinna/Biotecx, Houston, TX). RNA samples (10 jxg per lane) were separated by electrophoresis through a denaturing agarose gel (1.2% wt/voJ) containing 7.5% formaldehyde and transferred to a nylon membrane (Hybond N + ; Am ersham Corp., Arlington Heights, IL) according to the manufacturer's recommendations. For analysis of the mouse Ldlr expression, polyA + R N A was isolated using the PoIyATtract m R N A isolation kit (Promega Corp., Madison, WI). Blots were subsequently hybridized with 32P-Jabeled probes of human apo E cDNA (10), mouse Ldlr cD N A (mLDLRc90) (11) , and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA at 55°C in a solution containing 50% formamide. The intensity of the hybridization signal was quantified with a Phosphorlmager (Molecu lar Dynamics Inc., Sunnyvale, CA). The amounts of APOE*3-Leiden and LDL receptor m RN A were related to the level of GAPDH mRNA.
Hormone treatment. HFC-fed male and female transgenic mice 14 wk of age were injected subcutaneously along the back every 14 d with testosterone decanoate or estradiol decanoate dissolved in arachis oil. Blood sampling and serum analysis were performed before and after 28 d of hormone treatm ent as described above. Estradiol decanoate and testosterone decanoate were a kind gift from Drs. H. Verheul and F. Deckers, Organon International bvM Oss, The N eth erlands.
In vivo hepatic triglyceride production. A fter a 12-h fasting pe riod mice were injected intravenously with Triton WR1339 (500 mg/ kg body wt) (12) using 15% (wt/vol) Triton solution in 0.9% NaCl. A t 0, 45, and 90 min after injection blood samples were drawn and ana lyzed for triglycerides as described above. Production of hepatic tri glyceride was calculated from the slope of the curve and expressed as mmol/h per kg body wt. For calculation of mouse total serum volume we used the equation: serum volum e = 0.33 X body wt (13) .
Isolation and labeling o f V L D L . Blood was collected from six to eight fasted transgenic or 15-20 fasted nontransgenic mice. Sera were pooled and ultracentrifuged to obtain the VLDL fraction (d < 1.006 g/ml). V LD L cholesterol and triglyceride were determined enzymati cally as described above, and V LD L protein was determined using the method of Lowry et al. (14) . To determ ine apo B content of the VLDL, some 25 jig of V L D L protein was subjected to a 4-20% gradi ent SDS-PAGE. After staining with Coomassie brilliant blue R and destaining in 30% methanol/10% acetic acid the gels were scanned using an HP ScanJet Plus, Hewlett Packard, Santa Clara, CA, and the amount of apo B (100+48) relative to total protein was calculated. The percentage of total apo B ranged from 20 to 40% of total VLDL protein. V LD L was radiolabeled with ,25I by the iodine monochloride method (15). The fraction of l2ST-labe! present in apo B was deter mined by isopropanol precipitation (16, 17) and ranged from 30 to 65%.
In vivo removal o f 125¡-labeled V L D L -a p o B. Fasted mice were intravenously injected with 0.2 ml of 0.9% NaCl containing BSA (1 mg/ml) and 10 |xg of 125f-labeled VLDL. Blood samples of ^ 25 (xl were collected from the tail vein at t = 1, 3, 5, 10, 30, 60, and 90 min after injection. The serum content of l25I~labeled apo B was measured by isopropanol precipitation followed by counting !2SI-label. A bi exponential model was used to estimate the area under the I25I-apo B decay curve and subsequent calculation of VLDL-apo B kinetics. V LD L secretion rate was calculated from VLDL fractional catabolic rate and serum apo B pool. Since > 85% of serum apo B and triglyc erides were associated with the d < 1.006 lipoprotein fraction, we de termined the serum apo B pool by measuring serum triglyceride lev els 48 h before injection and the apo B to triglyceride ratio in the isolated d < 1.006 lipoproteins (V LD L) of mice from the same group (autologous). Serum triglycerides on 48 h before injection were ^ 20% higher as compared to serum triglyceride levels at the end of the turnover experiment. However, this decreasing effect was similar for all mice injected.
Results
Effect o f age, gender, and diet on serum lipid and lipoprotein levels. The increase in body weight with age for male and fe male transgenic and nontransgenic mice is shown in Fig* 1 Figure 1 . Age-and sex-dependent body weight. Body weight changes due to the increase in age were fol lowed over time in male (squares) and female (circles) mice fed an SRM-A diet (A) or an HFC diet (B). All groups contain at least 13 mice, which were weaned at day 25± i. Body weight was determined after an overnight fast. Values are expressed as m ean±SE (error bar not visible when SE < symbol size). Closed symbols, APOE*3-Leiden transgenic mice; open symbols, con trol mice. difference in growth rate was observed between transgenic and control mice and between both diets administered. At an early age, the gain in body weight was more rapid than at later age and more pronounced for male than for female mice. Fig. 2 (A-C) shows the effect of age on serum cholesterol (¿4), triglyceride (B), and the apo E3-Leiden protein levels (C) for SRM-A fed mice. At weaning, transgenic and nontrans genic animals showed comparable levels of serum cholesterol and triglycerides. Transgenic animals showed a rapid signifi cant increase (P < 0.01) in both serum cholesterol and triglyc erides with a maximum around 45 d of age. This postweaning increase was more pronounced for male than for female trans genic mice. Serum apo E3-Leiden levels also displayed a sig nificant increase (P < 0.01) in levels directly after weaning. However sex differences were not observed during this period. At an early age nontransgenic animals also showed an increase for both serum cholesterol and triglyceride levels, however this increase was less pronounced as compared to transgenic animals.
The increases at an early age in transgenics in levels of cho lesterol, triglycerides, and apo E3-Leiden appeared to be tran sient. After 150 d of age, serum cholesterol and triglycerides had decreased to almost basal levels of about 2.5 and 2.0 mmol/liter, respectively. At this age females had higher levels of cholesterol and triglycerides than males. In addition, fe- males showed significantly higher apo E3-Leiden levels than males (40 vs 18 mg/dl). Fig. 2 (D-F) shows the serum cholesterol, triglyceride, and apo E3-Leiden levels after feeding a cholesterol-rich HFC diet. The time course profiles for serum triglycerides (E) re sembled those observed after regular SRM-A feeding (.B), whereas after feeding HFC the respective levels of apo E3-Leiden (F) were about twice as high as during SRM-A feeding (C). At an early age, serum cholesterol levels (D) were two to threefold higher as compared to SRM-A feeding. In contrast to SRM-A feeding, HFC feeding led to prolonged elevated levels of cholesterol, although for males a slight decrease in se rum cholesterol levels to about 7.0 mmol/liter was observed at a later age.
Nontransgenic animals at an early age also showed in creased levels of cholesterol and triglycerides after feeding HFC diet, but to a much smaller extent as compared to trans genic animals. In contrast to transgenic mice, nontransgenic male mice at a later age had slightly higher lipid levels as com pared to nontransgenic females. Fig. 2 suggests that the effect of HFC feeding on lipid levels at an early age is a result of both age, as observed during SRM-A feeding, and an additional dietary component To study the ef fect of HFC feeding on serum lipid levels solely, mice of 200 d of age and fed a SRM-A diet were switched to the HFC diet. As illustrated in Fig. 3 A , transgenic animals displayed an in crease in serum cholesterol levels but less pronounced than at an early age (as shown in Fig. 2) , and again the females were more responsive than the males (up to 7.5 and 5.5 mmol/liter, respectively). Remarkably, serum triglycerides (B) showed only a small and transient increase, whereas apo E3-Leiden levels (C) strongly increased from 7 to 26 and from 30 to 90 for 
males and females, respectively. In nontransgenics, serum cho lesterol levels were much less severely elevated after feeding HFC diet at a later age, whereas serum triglyceride levels were not affected at all.
The results described above clearly indicate that serum lip ids in transgenic mice are affected by age, nutrition, and gen der. To investigate in which lipoprotein classes these changes in serum lipids mainly occur, we analyzed lipoprotein profiles by FPLC gelpermeation chromatography using a Superose 6B column and calculated the distribution of cholesterol among VLDL/LDL and HDL-sized lipoproteins, respectively. Feed ing both an SRM-A or HFC diet, the major changes in serum cholesterol were confined to the VLDL/LDL-sized fractions. In addition, the higher serum cholesterol levels in females as compared to males during the diets at a later age are also con fined to this lipoprotein fraction (results not shown).
We further investigated the effect of age and gender on hy perlipoproteinemia in the A FO E:f!3-Leiden mice, separately. For investigating the effect of age we used only young (45 d of age) and older (> 100 d of age) SRM-A fed male mice, since the effect of age on serum iipid levels was more pronounced in male than in female mice. For studying the effect of gender we used older male and female mice (> 100 d) fed an HFC diet, since the effect of gender on hyperlipoproteinemia was more pronounced in older than in young mice.
Effect of age on VLD L metabolism in vivo. Our previous study has shown that the level of hyperlipidemia corresponds to the expression level of the APOE*3-Leiden gene (8, 9) . To study whether the transient accumulation of VLDL/LDL sized lipoproteins at an early age on either diet is due to transient higher expression levels of the transgene, we determined APOE*3-Leiden mRNA in the liver by Northern blotting. Livers of mice with maximum hyperlipidemia (45 d of age) were compared to older mice (> 100 d of age). From the re sults presented in Table I , it is obvious that no significant dif ferences in E3-Leiden mRNA levels in the liver were observed between young and old male mice when fed a SRM-A diet. Feeding HFC diet resulted in slightly but not significantly ele vated levels of E3-Leiden mRNA as compared to SRM-A feeding. These results indicate that the age-dependent serum lipid and apo E3-Leiden protein levels were not related to changes in expression of the transgene.
To investigate whether the effect of age on serum levels of VLDL/LDL-lipoproteins was related to changes in endoge nous VLDL production by the liver we determined the in vivo hepatic VLDL-triglyceride production rate. Therefore, young male mice of 45 d of age and old male mice (> 100 d of age), both transgenic and nontransgenic, were injected with Triton WR1339 and the increase in serum triglycerides after injection was determined. As presented in Table II , VLDL-production rates were significantly affected by age, young male mice dis playing about 50% higher VLDL-triglyceride production rate than older mice irrespective of the presence of the APOE*3-Leiden transgene.
To investigate whether the effect of age on serum levels of VLDL/LDL-lipoproteins was also due to changes in VLDL clearance rate, in vivo VLDL turnover studies were per formed. Young male transgenic and nontransgenic mice of 45 d of age and old male transgenic mice (> 100 d of age), were injected with 10 jxg of autologous l25I-labeled VLDL, and the 125I-apo B disappearance from the circulation was determined* As illustrated in Fig. 4 A and presented in Table III , VLDL fractional catabolic rate (FCR) was clearly affected by trans gene expression. Young transgenic mice displayed a signifi cantly lower VLDL-FCR as compared to young nontransgenic mice. In contrast, no effect of transgene expression on VLDL secretion rate (VLDL-SR) was observed, indicating that the higher serum lipid levels in transgenic mice as compared to nontransgenic mice were due to an impaired VLDL clearance rate, as expected.
An age-related change in VLDL-FCR was not observed as young and old transgenic mice displayed comparable VLDL-FCR ( Fig. 4 B and Table III) , In contrast, a strong and signifi cant effect of age on VLDL-SR is observed (Table III, (Ta  ble II) .
Effect o f sex hormones on serum lipid levels and on VLDL metabolism in vivo. Maximal gender related differences in lipid levels in APOE*3-Leiden mice were observed at a later age (> 100 d) after feeding HFC. Thus, to investigate these gender related differences, older mice on an HFC diet were treated with either testosterone or estradiol. Mice were in- jected subcutaneously either a physiological or a pharmacolog ical dose of either hormone. As presented in Table IV , in male mice, treatment with estradiol resulted in a significant increase in serum triglyceride levels, whereas treatment with testoster one decreased serum cholesterol levels, although not signifi cantly. Also for female mice, treatment with estradiol resulted in significantly increased serum triglyceride levels, whereas treatment with a pharmacological dose of testosterone signifi cantly decreased both serum cholesterol and triglyceride levels.
To investigate in which lipoprotein classes these changes in serum lipid levels mainly occur, we generated lipoprotein pro files by FPLC gelpermeation chromatography using Superose 6B. In male mice ( Fig. 5 A) treatment with estradiol resulted in a slight dose-dependent decrease of HDL cholesterol, whereas an increase of cholesterol in the VLDL-sized lipoprotein frac tions is observed, thus, leading to an unaffected total serum cholesterol level as presented in Table IV . The decrease in se- 
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Van Vlijmen et a l rum cholesterol and triglycerides levels observed after testos terone treatment of female mice was confined to VLDL/LDL sized-lipoprotein fractions (Fig. 5 B) .
To investigate whether changes in lipid levels after hor mone treatment were initiated by changes in transgene expres sion, we also determined APOE*3-Leiden mRNA levels in the liver of both HFC-fed male and female mice, treated with either testosterone or estradiol. As presented in Table V, 
Fraction number Figure 5 . Distribution of serum cholesterol among lipoprotein frac tions after hormone treatment. Lipoprotein fractions were separated by permeation chromatography using a 25-ml Superose 6B column as described in Methods. Lipoprotein profiles are shown for male (A) and female transgenic mice (B ) which were treated with estradiol decanoate or testosterone decanoate, respectively. Each run is per formed with a pool of at least five mice of the same group. Fraction numbers 5-15 and 16-30 correspond to V LD L/LD L and HDL, re spectively. Solid, dashed, and dotted lines represent mice treated with placebo, physiological dose, and pharmacological dose of hormone, respectively (see Table IV ).
both males and females, estradiol administration had no signif icant effect on the expression of the APOE*3-Leiden gene. In contrast, administration of testosterone resulted in a signifi cant lowering of APOE*3-Leiden mRNA levels for both male and female mice. In a parallel experiment untreated male mice (placebo) displayed significantly lower expression of the A POE *3-Leiden transgene than untreated female mice (69.0± 14.5 versus 100±'13.2%). Since hepatic LDL receptors are known to be regulated by estradiol administration, at least in rats (18) (19) (20) and humans (21) , we also determined LDL recep tor mRNA levels in estradiol-treated female mice. In female mice hepatic Ldlr mRNA levels were not affected by estradiol administration (100±25.3 versus 102±25.9% for placebo and estradiol treated animals, respectively). We investigated whether the changes in serum levels of VLDL/LDL-sized lipoproteins upon sex hormone administra tion were related to a concurrent change in hepatic VLDL triglyceride production rate. As presented in Table VI , placebo-treated female mice displayed a significantly higher VLDL-triglyceride production rate as compared to placebotreated male mice. VLDL-triglyceride production rate in fe male mice did not change upon testosterone treatment, whereas a 20% increase in VLDL-triglyceride production rate was observed in males after estrogen treatment.
To evaluate whether sex hormones were also influencing the plasma clearance rate of VLDL, we performed in vivo VLDL turnover studies. Placebo-treated male and female mice displayed comparable VLDL-FCR's (Table VII) . As il lustrated in Fig. 6 A and presented in Table VII , VLDL-FCR in males decreased significantly after estrogen treatment, whereas a significant increase in VLDL-FCR was observed in females after testosterone treatment (Fig. 6 B ; Table VII ). Op posite effects were observed for VLDL-SR: VLDL-SR in male mice increased after estrogen treatment, whereas a slight de crease in VLDL-SR is observed in female mice after testoster one treatment. In addition, placebo-treated female mice dis played a higher VLDL-SR as compared to placebo treated After an overnight fast hormone treated APOE*3-Leiden transgenic mice were injected with Triton WR1339 (see Methods). The serum tri glycerides were determined just before injection (0 min) and at 45 and 90 min after Triton injection. Hepatic VLDL triglyceride production rate was calculated from the slope of the curve and is expressed as mmol/h/kg body wt. Values are the m ean±SD, Since two independent experiments are combined to increase the number of animals per groups (n = 14-16) values are expressed as a percentage of the hepatic VLDL triglyceride production in placebo treated male mice in the same experi ment. *P < 0.05, indicating the difference between male and female mice, using nonparametricMann-W hitney test. ND; not determined. male mice. Although these effects on VLDL-SR were not sig nificant, these changes in VLDL-SR correspond with changes upon hormone treatment in serum lipid levels (Table IV) and in hepatic VLDL-triglyceride production rate (Table VI) .
Discussion
In the present study we showed that hyperlipidemia in APOE*3-Leiden mice was severely affected by age ( Figs. 2  and 3 ). At early age in the APOE*3-Leiden mice an enhanced production of hepatic VLDL was observed, whereas the plasma clearance of VLDL was not age dependent (Tables II  and III) . Apparently, since APOE*3-Leiden mice are unable to efficiently remove VLDL remnants from the circulation Table III) , the extra supply of newly synthesized hepatic VLDL, as occurring during rapid growth, is primarily responsible for the enhanced accumulation of these lipopro teins in the plasma at young age. Increased VLDL production rate has also been reported to occur in young rapidly growing rats, due to a stimulation of the hepatic triglyceride synthesis by growth hormone (22, 23) . In adult humans VLDL synthesis is also known to be stimulated upon body weight gain. Similar to APOE:iî3-Leiden mice, in humans carrying mutant APOE alleles, like APOE*3-Leiden, APOE*2(Lysl46-»Gln) and the APOE*2(Argl58->Cys), high body weight and body weight gain are strong aggravating factors in the accumulation of VLDL remnants (familial dysbetalipoproteinemia) (1, 6, 24) . APOE*3'-Leiden transgenic mice displayed a marked ef fect of gender on the expression of hyperlipidemia ( Figs. 2 and  3 ). Estrogens increase serum lipid levels, whereas testosterone showed the opposite effect (Table IV, Fig. 5 ). Previously, we reported that in APOE*3-Leiden mice the level of serum lip ids is positively correlated with the level of the expression of the transgene in the liver (9) . In the present study we found that expression of the APOE^3-Leiden gene results in a re duced clearance rate of VLDL, whereas the production of VLDL was not affected by the presence of the transgene (Ta  ble III) . Thus, the observation that testosterone administration results in a reduced expression of the APOE*3-leiden trans gene in the liver (Table V) can explain why testosterone ad ministration resulted in lower serum VLDL/LDL lipoprotein levels, i.e., testosterone increases the clearance rate of VLDL, without an effect of testosterone on VLDL production rate (Table VI and VII). The reason for the effect of testosterone on the expression of the transgene is at present subject to spec ulation, Transgene expression was not affected by estrogen ad ministration (Table V) and thus cannot explain the observed reducing effect of estrogen on VLDL clearance (Table VII) .
We present evidence that the increased serum lipid levels ob served in females, and after estrogen administration in males (Table IV) can, at least partly, be explained by a relatively high rate of VLDL production (Table VI and VII) .
The respective effects of both steroid hormones on the se rum lipids and lipoprotein profile, hepatic VLDL triglyceride production and VLDL-apo B secretion are in line with the ob served differences in lipid levels between untreated male and female APOE*3-Leiden mice. However, although both tes tosterone and estrogen treatment displayed considerable but opposing effects on VLDL clearance rate, differences in VLDL clearance were not found between untreated male and female mice. Similarly, although estrogens decreased VLDL clearance rate in males, the only significant difference between untreated males and females was increased VLDL production rate in females. These observations suggest discrepancies in the overall observed gender effect. However, in untreated males and females endogenous sex hormones form only part of the whole set of factors determining the final phenotype. The use of castrated males and ovariatectomized females in stead of the respective sex hormone injected animals might have avoided these apparent discrepancies. In this study, addi tion of (supra) physiological doses of exogenous sex hormones was carried out only to evaluate the direction of the effect rather than that it aimed to extrapolate the effect to the basal in vivo situation in a quantitative sense.
Clearly, estrogens play an important role in mediating the gender differences observed in APOE*3-Leiden mice. The es trogen-mediated stimulation of hepatic VLDL production is well documented for humans (25) and rats (26) and suggests estrogen to be a risk factor for FD. Paradoxically, in humans FD is more prevalent in men than in women (1) and estrogenreplacement therapy is frequently used in reducing the expres sion of FD (27) . Obviously, in humans estrogens play a protec tive rather than an aggravating role in the accumulation of VLDL remnant lipoproteins. An explanation for this benefi cial effect of estrogens in humans is commonly assumed to be the fact that estrogens stimulate the expression of hepatic LDL receptors (18) (19) (20) (21) . The fact that an increase in hepatic LDL re ceptor mRNA upon estrogen treatment does not occur in hamsters and mice (28-30) including the present APOE*3-Leiden transgenic mice, could explain the opposing effects of estrogen in humans and mice regarding the accumulation of remnants.
It could be possible that in mice hepatic LDL receptor ac tivity is less susceptible to regulation than it is in humans. This is also supported by the observations that feeding C57BL/6J mice a high fat/cholesterol diet results in downregulation of HMG-CoA reductase activity whereas LDL receptor expres sion is relatively unaffected (31, 32) . We hypothesize that an increased hepatic VLDL production increases the hepatic demand for cholesterol, but in mice this is not followed by upregulation of hepatic LDL receptors like in humans. Con sequently, in APOE*3-Leiden mice, which are unable to effi ciently metabolize hepatic lipoproteins, the increase in VLDL production upon the administration of estrogen will not be compensated by a simultaneous upregulation of LDL recep tors and, thus, will lead to an extra accumulation of these lipo proteins in the plasma.
For the APOE*3-Leiden mice used in the present study> the APOC1 gene was included to be sure to have included an element that mediates liver-specific expression of the apo E gene. Recently, we have generated transgenic mice express ing the APO E* 3-Leiden gene without the human APO Cl gene but containing the hepatic control region mediating liver expression. These mice have comparable expression of the APOEii:3-Leiden transgene on the level of mRNA and on the level of serum apo E protein. In addition, these mice display similar diet-induced hyperlipoproteinemia and also show a similar effect of age and gender on the hyperlipidemic pheno type (results not shown). Hence, a role for the human APOC1 gene in inducing the age-and sex-dependent hyperlipidemic phenotype can be excluded.
Transgenic mice expressing the defective A PO E(A rgll2, Cys'142) variant, also display diet-induced elevated levels of plasma cholesterol and triglycerides due to the accumulation of remnant lipoproteins (33, 34) . However, in these mice a sim ilar gender-and age-related effect on plasma lipid levels has not been reported. On the contrary, in heterozygous apo E-defi cient mice elevated plasma Jipid levels in females as compared to males have also been observed, after being fed severe cho lesterol-rich diets (35). Such a gender effect has not been re ported (35-39) in homozygous apo E deficient mice, either due to the extreme phenotype of these mice under normal condi tions or the absence of apo E itself.
In this study, we have shown that age-and gender-related changes in serum lipid levels of APOE*3-Leiden mice at least in part were related to mild changes in hepatic VLDL produc tion. These results are consistent with our previous study (9) showing that the serum lipid levels in A POEsii3-Leiden mice are also highly responsive to sucrose feeding which is known to increase hepatic lipogenesis and thereby the production and secretion of VLDL triglyceride by the liver (7, 40, 41) . We con clude that introducing a defective apo E, like in the APOE*3-Leiden transgenic mice, leads to a high responsiveness of the serum lipid levels to relative mild changes in chylomicron and VLDL production rate. Consequently, this animal model can easily be used for studying the effect on plasma lipid levels of (subtle) environmental factors, like nutrition and drugs that are supposed to modulate VLDL production in the liver or lipid absorption and chylomicron production in the intestine. In addition, our results strongly sustain the hypothesis that in carriers of mutant apo E alleles the production rate of both liver and intestinal lipoproteins are important determinants of the clinical expression of familial dysbetalipoproteinemia.
